Merck's Keytruda shrinks lung cancer tumors, FDA approval sought

April 19, 2015 12:35 PM

2 0

(Reuters) - Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.

The company said it has filed for U.S. Food and Drug Administration approval of the drug as a treatment for patients with non-small cell lung cancer (NSCLC) whose disease has worsened despite previous treatment.

Read more

To category page